NasdaqCM - Nasdaq Real Time Price USD

Nektar Therapeutics (NKTR)

0.7964

+0.0719

+(9.92%)

At close: June 2 at 4:00:00 PM EDT

0.7800

-0.02

(-2.06%)

After hours: June 2 at 7:45:16 PM EDT

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

The analysts might have been a bit too bullish on Nektar Therapeutics ( NASDAQ:NKTR ), given that the company fell...

Simply Wall St. 19 days ago

NKTR
+9.92%
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City on May 20, 2025:

PR Newswire 20 days ago

NKTR
+9.92%
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook

One thing we could say about the analysts on Nektar Therapeutics ( NASDAQ:NKTR ) - they aren't optimistic, having just...

Simply Wall St. 20 days ago

NKTR
+9.92%
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations

Nektar Therapeutics ( NASDAQ:NKTR ) First Quarter 2025 Results Key Financial Results Revenue: US$10.5m (down 52% from...

Simply Wall St. 22 days ago

NKTR
+9.92%
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.

Zacks 24 days ago

NKTR
+9.92%

LLY
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising pipeline developments and a strong cash position.

GuruFocus.com 24 days ago

NKTR
+9.92%
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of -22.22% and 40.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 25 days ago

NKTR
+9.92%
Nektar: Q1 Earnings Snapshot

SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $50.9 million in its first quarter. On a per-share basis, the San Francisco-based company said it had a loss of 24 cents. Losses, adjusted for non-recurring costs, came to 22 cents per share.

Associated Press Finance 25 days ago

NKTR
+9.92%
Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025.

PR Newswire 25 days ago

NKTR
+9.92%
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

PR Newswire last month

NKTR
+9.92%
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

NKTR
+9.92%

NOTV
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

Nektar shares jumped 26% Friday following the upgrade, despite a six-month decline of over 63%.

GuruFocus.com last month

NKTR
+9.92%
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

NKTR
+9.92%

CPRX
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6% in a month while the […]

Insider Monkey 2 months ago

NKTR
+9.92%

^GSPC
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference:

PR Newswire 2 months ago

NKTR
+9.92%
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

NKTR
+9.92%
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Nektar Therapeutics ( NASDAQ:NKTR ) Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from FY...

Simply Wall St. 2 months ago

NKTR
+9.92%
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.

Zacks 2 months ago

NKTR
+9.92%
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a strong cash position.

GuruFocus.com 2 months ago

NKTR
+9.92%

Performance Overview

Return	NKTR	S&P 500 (^GSPC)
YTD	-14.37%	+0.92%
1-Year	-37.29%	+12.48%
3-Year	-78.24%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

Nektar: Q1 Earnings Snapshot

Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Performance Overview